

Gata6 potently initiates reprogramming of pluripotent and differentiated cells to extraembryonic endoderm stem cells

Sissy E. Wamaitha,¹ Ignacio del Valle,¹ Lily T.Y. Cho,^{1,4} Yingying Wei,^{2,5} Norah M.E. Fogarty,¹ Paul Blakeley,¹ Richard I. Sherwood,³ Hongkai Ji,² and Kathy K. Niakan¹

¹Mill Hill Laboratory, The Francis Crick Institute, London NW7 1AA, United Kingdom; ²Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA; ³Brigham and Women's Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA

Transcription factor-mediated reprogramming is a powerful method to study cell fate changes. In this study, we demonstrate that the transcription factor Gata6 can initiate reprogramming of multiple cell types to induced extraembryonic endoderm stem (iXEN) cells. Intriguingly, Gata6 is sufficient to drive iXEN cells from mouse pluripotent cells and differentiated neural cells. Furthermore, GATA6 induction in human embryonic stem (hES) cells also down-regulates pluripotency gene expression and up-regulates extraembryonic endoderm (ExEn) genes, revealing a conserved function in mediating this cell fate switch. Profiling transcriptional changes following Gata6 induction in mES cells reveals step-wise pluripotency factor disengagement, with initial repression of *Nanog* and *Esrrb*, then *Sox2*, and finally *Oct4*, alongside step-wise activation of ExEn genes. Chromatin immunoprecipitation and subsequent high-throughput sequencing analysis shows Gata6 enrichment near pluripotency and endoderm genes, suggesting that Gata6 functions as both a direct repressor and activator. Together, this demonstrates that Gata6 is a versatile and potent reprogramming factor that can act alone to drive a cell fate switch from diverse cell types.

[Keywords: reprogramming; pluripotency; mouse embryonic stem cells; human embryonic stem cells; extraembryonic endoderm; Gata6]

Supplemental material is available for this article.

Received December 9, 2014; revised version accepted May 21, 2015.

One of the earliest specification events during mammalian development is the divergence of pluripotent epiblast progenitor (EPI) cells, which give rise to the embryo proper, and primitive endoderm (PrE) cells, which mainly contribute to the yolk sac. In mice, embryonic stem (ES) cells and extraembryonic endoderm stem (XEN) cells can be derived from the EPI and PrE lineages, respectively, and retain characteristics of their cell type of origin (Evans and Kaufman 1981; Martin 1981; Kunath et al. 2005). Mouse ES (mES) cells are able to self-renew and remain pluripotent and depend on a gene regulatory network surrounding the core transcription factors Oct4, Sox2, and Nanog (Boyer et al. 2005; Loh et al. 2006; Chen et al. 2008). Transcription factors such as Esrrb and Klf4 are also regulated by and reinforce the core pluripotency factors (Ivanova

et al. 2006; van den Berg et al. 2008; Zhang et al. 2008; Hall et al. 2009; Niwa et al. 2009; Festuccia et al. 2012).

In contrast, PrE and self-renewing XEN cells lack expression of pluripotency genes and require an extraembryonic endoderm (ExEn) program, including transcription factors Gata4, Gata6, Sox7, and Sox17 (Soudais et al. 1995; Arman et al. 1998; Morrisey et al. 1998; Koutsourakis et al. 1999; Futaki et al. 2004; Capo-Chichi et al. 2005; Kunath et al. 2005; Chazaud et al. 2006; Shimoda et al. 2007; Brown et al. 2010b; Morris et al. 2010; Niakan et al. 2010; Artus et al. 2011; Schrode et al. 2014). It remains unclear how cells within the early embryo diverge to favor either a pluripotency or an ExEn gene regulatory network. The overexpression of the zinc finger transcription factor Gata6 or Gata4 is sufficient to reprogram mES cells into XEN-like cells that contribute to PrE-derived lineages in vivo (Fujikura et al. 2002; Shimosato et al. 2007). The GATA factors are therefore part of a subset of transcription factors that are capable of inducing cellular reprogramming, although precisely how this occurs

Present addresses: ⁴Neusentis, Pfizer Worldwide Research and Development, Great Abington, Cambridge CB21 6GS, UK; ⁵Department of Statistics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

Corresponding author: kathy.niakan@crick.ac.uk

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.257071.114>. Freely available online through the *Genes & Development* Open Access option.

© 2015 Wamaitha et al. This article, published in *Genes & Development*, is available under a Creative Commons License (Attribution 4.0 International), as described at <http://creativecommons.org/licenses/by/4.0/>.

has yet to be elucidated. Ectopic expression of the transcription factor MyoD converts fibroblasts to myogenic cells (Davis et al. 1987), a combination of transcription factors reprograms fibroblasts to induced pluripotent stem (iPS) cells (Takahashi and Yamanaka 2006), and in vivo pancreatic exocrine cells can be reprogrammed into insulin-secreting β -like cells (Zhou et al. 2008). Similarly, overexpression of Cdx2 is sufficient to reprogram mES cells to trophoblast-like cells that contribute solely to placental lineages in vivo (Niwa et al. 2005). However, the mechanisms by which single transcription factors reprogram existing gene expression patterns toward that of their target cell type remain unclear.

Induction of the SRY homeobox gene *Sox17* has also been shown to induce ExEn gene expression in mES cells (Niakan et al. 2010; McDonald et al. 2014). Intriguingly, *SOX17* induction in human ES (hES) cells instead drives an embryonic endoderm program (Seguin et al. 2008). This incongruence is consistent with our previous observations that the initial ES cell state influences differentiation outcomes (Cho et al. 2012). Furthermore, while the induction of *SOX7* drives ExEn gene expression in hES cells (Seguin et al. 2008), stable self-renewing human XEN cells have yet to be established. The effect of GATA factor induction in hES cells has not been tested, and it is unclear whether *Gata6* can function as a master transcriptional regulator to induce a XEN program from cells other than mES cells.

We developed a highly efficient approach to understand the molecular mechanisms of *Gata6*-mediated reprogramming and show that *Gata6* is a potent inducer of lineage reprogramming in multiple cell types. We demonstrate that a short pulse of *Gata6* induction is ample to perturb gene expression in mES cells and initiate conversion to induced XEN (iXEN) cells, while longer induction fully down-regulates the pluripotency program. Using genome-wide transcriptional and chromatin immunoprecipitation (ChIP) analyses, we found that *Gata6* is able to rapidly and directly inhibit core and peripheral genes within the pluripotency regulatory network as well as directly activate an ExEn program. Despite lingering expression of Oct4 following *Gata6* induction, loss-of-function analysis suggests that Oct4 is not required to drive this lineage switch in mES cells. *Gata6* expression in more committed neural cells also drives reprogramming to iXEN-like cells. We show that *GATA6* induction in hES cells initiates ExEn expression and is sufficient to inhibit core pluripotency gene expression. Our findings have important implications for understanding how transcription factors function to drive a cell fate switch and provide fundamental insights into early mammalian cell fate specification.

Results

Gata6 or *Gata4* expression is uniquely sufficient to induce rapid reprogramming of mES cells to iXEN cells

While *Gata4* and *Gata6* are able to reprogram mES cells, it is unclear whether other endoderm transcription factors are also able to mediate this cell fate switch. We selected

six transcription factors (*Gata4*, *Gata6*, *Hnf4a*, *Foxa3*, *Sox7*, and *Sox17*) that are expressed in the PrE or its derivatives and are functionally required to establish or maintain this lineage (Chen et al. 1994; Soudais et al. 1995; Molkenin et al. 1997; Kaestner et al. 1998; Morrissey et al. 1998; Koutsourakis et al. 1999; Capo-Chichi et al. 2005; Artus et al. 2011; Schrode et al. 2014). To investigate whether their expression is sufficient to induce reprogramming of mES cells to iXEN cells, we used a site-specific recombination-based integration strategy (Hochedlinger et al. 2005; Beard et al. 2006) to generate mES cells expressing a single copy of a tetracycline/doxycycline-inducible *Gata4*, *Gata6*, *Sox7*, *Sox17*, *Hnf4a*, or *Foxa3* transgene. To test the fidelity of the system, we also engineered control mES cells that induce the expression of a gene encoding a red fluorescent protein, *dsRed*. We confirmed robust induction above or close to levels present in embryo-derived XEN (eXEN) cells by quantitative RT-PCR (qRT-PCR) analysis of the Flag- or V5-tagged transgene (Supplemental Fig. S1A). We also observed robust red fluorescence in *dsRed*-overexpressing mES cells (Supplemental Fig. S1B).

To determine the effect of these factors under conditions that would otherwise maintain pluripotency, we induced exogenous expression with doxycycline for 6 d in the presence of LIF and serum, which are known to maintain mES cell self-renewal indefinitely in culture (Fig. 1A). *Gata6* or *Gata4* overexpression resulted in reprogramming to cells with the dispersed, refractile, and stellate morphology characteristic of eXEN (Fig. 1B) and growth factor-converted XEN (cXEN) cells (Kunath et al. 2005; Cho et al. 2012). qRT-PCR analysis of the 3' untranslated region (UTR) confirmed that *Gata6*- or *Gata4*-induced cells expressed endogenous *Gata6* and *Gata4* as well as key ExEn genes, including *Sox7*, *Sox17*, *Lama1*, *Col4a1*, *Sparc*, *Dab2*, *Foxa3*, and *Hnf4a*, to levels above or close to those present in eXEN cells (Fig. 1C; Supplemental Fig. S1C). Immunofluorescence analysis also confirmed that both *Gata4*-induced (data not shown) and *Gata6*-induced cells express *Gata4*, *Gata6*, *Sox17*, and Laminin proteins (Fig. 1D). Moreover, *Gata6*-induced cells no longer expressed Oct4 protein (Fig. 1D), suggesting that they have been reprogrammed to iXEN cells.

In contrast, expression of *Sox7*, *Sox17*, *Hnf4a*, or *Foxa3* failed to induce a morphological switch to XEN-like cells within 6 d of induction (Fig. 1A). These factors inconsistently up-regulated ExEn genes and failed to up-regulate the expression of factors such as *Col4a1*, *Lama1*, or *Hnf4a* to eXEN cell levels (Fig. 1C; Supplemental Fig. S1C,D). We and others have previously observed that *Sox17*-overexpressing cells retained mES cell-like morphology and the expression of *Pou5f1*, *Sox2*, and *Nanog* after 48 h of induction (Niakan et al. 2010; McDonald et al. 2014). Similarly, *Sox17*, *Sox7*, or *Foxa3* levels of *Pou5f1*, *Nanog*, and *Sox2* were comparable with the expression in *dsRed* control cells after 6 d of induction (Fig. 1C). Moreover, *Sox7*-expressing colonies retain mES cell-like morphology and persistently express Oct4 protein despite a few *Gata4*-, *Gata6*-, *Sox17*-, and Laminin-expressing cells at the periphery of colonies (Fig. 1D).




Figure 1. *Gata6* or *Gata4* induction is uniquely sufficient to reprogram mES cells to XEN cells. (A) Representative phase-contrast images of *dsRed*-, *Foxa3*-, *Hnf4a*-, *Gata4*-, *Gata6*-, *Sox7*-, or *Sox17*-induced cells after 6 d of doxycycline treatment in the presence or absence of LIF. Bars, 100 μ m. (B) Phase-contrast images of uninduced mES cells and eXEN cells. (C) qRT-PCR analysis for selected pluripotency and endoderm transcripts in *dsRed*-, *Foxa3*-, *Hnf4a*-, *Gata4*-, *Gata6*-, *Sox7*-, or *Sox17*-induced cells after 6 d of doxycycline treatment in the presence (solid) or absence (checked) of LIF. Relative expression reflected as fold difference over uninduced mES cells normalized to *Gapdh*. Data are mean \pm SEM of two to three biological replicates and four technical replicates. (*) $P < 0.05$; (**) $P < 0.01$; (***) $P < 0.001$. (D) Immunofluorescence analysis for *Gata4*, *Gata6*, *Sox17*, Laminin, or Oct4 (all green) with DAPI merge (blue) in uninduced mES cells or *Sox7*- or *Gata6*-overexpressing mES cells after 6 d of doxycycline treatment.

We next induced transgene expression in the absence of LIF to determine whether destabilizing pluripotency via altered culture conditions would facilitate *Sox7*, *Sox17*, *Hnf4a*, or *Foxa3* induction of mES to iXEN cell reprogramming within 6 d. Furthermore, as activation of FGF signaling is required for PrE development and derivation of XEN cells routinely involves addition of exogenous FGF (Feldman et al. 1995; Arman et al. 1998; Kunath et al. 2005; Chazaud et al. 2006; Yamanaka et al. 2010; Grabarek et al. 2012; Kang et al. 2013; Niakan et al. 2013), we also induced transgene expression in the presence of exogenous Fgf4 and heparin, which facilitates FGF receptor binding.

Although the induced cells lost their mES cell-like morphology, again, only *Gata6* or *Gata4* expression resulted in iXEN cell reprogramming within the 6-d time period (Fig. 1A,C; Supplemental Fig. S1C–E). Additionally, we observed little difference in overall gene expression between the FGF-supplemented and LIF-deficient conditions, suggesting that exogenous FGF signaling does not enhance reprogramming of mES cells to iXEN cells. In contrast *Sox7*-, *Sox17*-, *Hnf4a*-, or *Foxa3*-induced cells appeared to sporadically differentiate following LIF withdrawal. Despite the down-regulation of *Pou5f1*, *Sox2*, and *Nanog*, these cells did not exhibit XEN-like morphology and inconsistently up-regulated some but not all ExEn genes within this time frame. Altogether, this suggests that *Gata6* or *Gata4* induction is uniquely able to rapidly reprogram mES cells to iXEN cells. For subsequent experiments, we chose to use *Gata6* transgenic mES cells, as *Gata6* mutant embryos exhibit an early PrE deficiency, and *Gata6* is thought to lie upstream of *Gata4* in the PrE transcriptional hierarchy (Morrissey et al. 1998; Koutsourakis et al. 1999; Chazaud et al. 2006; Plusa et al. 2008; Artus et al. 2011; Schrode et al. 2014). Furthermore, all inductions were performed in the presence of serum and LIF, as the absence of LIF alone destabilizes pluripotency gene expression.

A short pulse of Gata6 induction is sufficient to perturb the mES cell state

We next sought to investigate the minimum temporal requirement for *Gata6* induction to affect mES cell gene expression. We induced exogenous expression for defined pulses of between 2 and 12 h and fixed the cells for immunohistochemistry immediately following doxycycline withdrawal (Fig. 2A). Flag and *Gata6* protein expression was detectable by immunofluorescence and Western blot analysis 2–4 h following doxycycline addition (Fig. 2B; Supplemental Fig. S2A). Although induced cells retained mES cell morphology over the initial pulse period, we observed a clear effect on protein expression, with *Nanog* protein down-regulated 8–10 h following induction (Fig. 2B).

To examine gene expression dynamics in more detail, we performed qRT–PCR analysis between 2 and 12 h following *Gata6* induction (Fig. 2C). qRT–PCR amplification of the Flag region confirmed robust induction of exogenous Flag-tagged *Gata6* by 2 h after doxycycline induction and more than twofold down-regulation of *Nanog*

by 6 h, followed by *Sox2* and *Esrrb* at 8 and 12 h, respectively. Western blot analysis over the 12-h period confirmed these dynamics, with steady down-regulation of *Nanog* (Supplemental Fig. S2A). However, *Pou5f1* expression was unchanged at these early time points (Fig. 2C). In contrast, endogenous *Gata6* and *Gata4* were up-regulated more than twofold relative to uninduced controls within 2 h of doxycycline induction. This was followed by greater than twofold up-regulation of *Sox17* and *Pdgfra* 4 and 6 h after induction, respectively.

We also followed the fate of pulse-induced cells for 48 h after they were returned to pluripotency maintenance medium in the absence of doxycycline (Fig. 2D). Over the 48-h period, cells induced from 6 to 12 h up-regulated *Sox17* expression, suggesting that *Gata6* had initiated the endogenous XEN program (Fig. 2E). Consistent with this, flow cytometry analysis of *Nanog* expression in *Gata6* pulsed cells identified a gradual reduction of median *Nanog* expression with increased *Gata6* induction time periods (Fig. 2F; Supplemental Fig. S3). This suggests that the induction of *Gata6* leads to the inhibition of *Nanog* in most cells. Importantly, similar analysis in the pulse-chased cells reveals a similar shift and indicates that, by 8 h of exogenous *Gata6* expression, most of the cells do not re-express *Nanog* (Fig. 2F; Supplemental Fig. S3). However, we occasionally observed some cells that retained *Nanog* expression (Fig. 2E). As heterogeneities in *Nanog* expression are known to exist within mES cell cultures (Chambers et al. 2007), this suggests that these cells likely have a higher threshold of pluripotency gene expression to overcome.

Stable iXEN cell lines were successfully derived from *Gata6*-expressing cells induced for 6–12 h and were maintained in the absence of doxycycline for >10 passages. qRT–PCR analysis confirmed that stable iXEN cells maintain XEN gene expression and do not re-express pluripotency genes (Supplemental Fig. S2B). We next sought to test the developmental potential of iXEN cells by generating chimera embryos. We injected unlabeled iXEN cells into B5/EGFP embryonic day 3.5 (E3.5) blastocysts that constitutively express EGFP (Hadjantonakis et al. 1998). We then analyzed chimera contribution in E5.5–E6.5 embryos (Fig. 2G,H). In the majority of chimera embryos (20 of 24), iXEN cells contributed to either the extraembryonic visceral or parietal endoderm, and we did not detect epiblast contribution. This confirms that, similar to previous studies using eXEN cells (Kunath et al. 2005), our iXEN cells were also capable of successful XEN contribution in chimera embryos.

To gain further insight into the developmental potential of iXEN cells, we introduced single unlabeled iXEN cells into B5/EGFP E2.5–E3.5 embryos via morula aggregation or blastocyst injection and analyzed chimera contribution at the blastocyst stage (Fig. 2G,I; Supplemental Fig. S2C). The majority of stable iXEN cells contributed to *Sox17*-expressing PrE cells in chimeras (25 of 38). Interestingly, when we introduced single *Gata6* 12-h pulse or 12-h pulse-chase cells, we found that while a similar number of chimera embryos had exclusive *Sox17* expression, the 12-h pulse-chase cells had a lower contribution to




Figure 2. A short pulse of *Gata6* induction initiates iXEN cell reprogramming (A) Time line of induction experiments. Cells were pulsed for incremental 2-h time periods and, at the end of each period, were analyzed by either immunohistochemistry, qRT-PCR, or flow cytometry. (B) Immunofluorescence analysis for Flag (green), *Gata6* (red), and DAPI (blue) merge or with Nanog (green), Sox17 (red), and DAPI (blue) merge in *Gata6*-induced cells immediately after doxycycline treatment for the defined periods. Bars, 20 μ m. (C) qRT-PCR analysis for exogenous Flag-tagged *Gata6* expression and selected pluripotency and endoderm transcripts in *Gata6*-overexpressing mES cells between 0 and 12 h of doxycycline induction. Relative expression is reflected as fold difference over uninduced mES cells normalized to *Gapdh*. Data are mean \pm SEM of two biological replicates. (D) Time line of induction pulse-chase experiments. Cells were pulsed for incremental 2-h time periods and, at the end of each period, were switched into pluripotency medium for 48 h and then analyzed by immunohistochemistry or flow cytometry or switched into pluripotency medium to derive stable iXEN cells. (E) Immunofluorescence analysis for Nanog (green), Sox17 (red), and DAPI (blue) merge in *Gata6*-induced cells treated with doxycycline treatment for the defined periods and then switched into pluripotency medium for 48 h. Bars, 20 μ m. (F) Flow cytometry analysis of Nanog expression at the defined time points in the pulse and pulse-chase cells. (G-I) Chimera contribution of unlabeled *Gata6*-induced cells injected into B5/EGFP embryos that constitutively express EGFP. (G) Summary of the number of cells injected, the stage of injection and dissection, and chimera contribution. (H) Embryonic day 5.5 (E5.5)-E6.5 post-implantation embryos with unlabeled iXEN cell contribution to the visceral (arrow) or parietal (arrowhead) endoderm. Representative images of chimeras with phase-contrast, DAPI (blue) nuclear staining, and embryo EGFP expression. (I) E3.5-E4 chimera blastocysts immunofluorescently analyzed for the expression of the PrE marker Sox17 (red), the epiblast marker Nanog (white), EGFP (green), and DAPI (blue) merge. Bars, 100 μ m.

Nanog-expressing cells (Fig. 2G,I; Supplemental Fig. S2C). This suggests that while *Gata6* is potent and highly efficient in initiating iXEN cell reprogramming, a sufficient time interval is required to commit to a XEN program.

To further unravel the mechanisms of *Gata6*-mediated reprogramming, we chose to investigate the effect of *Gata6* induction over a 6-d (144-h) period, as we had previously observed complete down-regulation of *Nanog*, *Oct4*, and *Sox2* by this time point. We analyzed defined time points between 12 and 144 h of induction to evaluate morphology and gene expression dynamics. From 24 h following *Gata6* induction, mES cell colonies changed from a domed to a flattened shape as cells migrated away from the center of the colony and eventually became refractile, rounded, and dispersed, similar to eXEN cells (Fig. 3A). qRT-PCR analysis confirmed that *Nanog* and *Sox2* transcripts were rapidly down-regulated within 12 h of doxycycline induction, with protein expression decreasing to levels below detection within 24 and 36 h, respectively (Fig. 3B,C). *Pou5f1* transcript and Oct4 protein displayed prolonged expression until 48 h after induction but were down-regulated by 96 h.

The qRT-PCR analysis also showed >10-fold up-regulation of ExEn genes between 12 and 48 h following doxycycline treatment (Fig. 3B). Interestingly, despite up-regulation of *Gata4* and *Sox17* transcripts within 12 h of *Gata6* induction (Fig. 2C), their proteins were not detectable by Western blot until 24 h following doxycycline treatment (Fig. 3C). Given that *Nanog*, *Esrrb*, and *Sox2* are down-regulated in the absence of detectable *Gata4* or *Sox17* protein, this suggests that *Gata6* directly mediates initial down-regulation of the pluripotency program. Despite robust induction of exogenous *Sox17* over the 144-h period, these cells retained expression of *Nanog* and *Oct4* (Fig. 3D) and show delayed up-regulation of endoderm factors compared with *Gata6* (Fig. 1C). This is consistent with recent findings that *Sox17*-expressing cells only acquire XEN-like morphology and down-regulate pluripotency factor expression after 12 and 18 d of induction, respectively (McDonald et al. 2014). Altogether, this shows that *Gata6* is uniquely able to rapidly down-regulate the core components of the pluripotency gene regulatory network and promote an ExEn program even in conditions that favor mES cell maintenance.

Gata6 can induce reprogramming of mES cells independently of Oct4 expression and Fgf4 signaling

Oct4 has been shown to be required for *Fgf4*-mediated PrE specification within the mouse embryo (Frum et al. 2013; Le Bin et al. 2014). Although *Gata6* expression is initiated in *Oct4* or *Nanog* mutant embryos, the subsequent absence of *Sox17* and *Gata4* suggests that PrE formation is compromised (Frankenberg et al. 2011; Frum et al. 2013; Le Bin et al. 2014). Given the persistent expression of *Pou5f1*/*Oct4* following *Gata6* induction, we sought to investigate the interplay between *Gata6*, *Oct4*, and *Fgf4* during mES cell reprogramming.

To investigate the requirement for *Oct4*, we introduced shRNAs directed against *Pou5f1* simultaneously

with doxycycline-induced expression of *Gata6* (Fig. 3E, F). We confirmed loss of *Pou5f1* expression by qRT-PCR (Fig. 3E) and *Oct4* protein by Western blot analysis (Fig. 3F). Despite the premature loss of *Oct4*, *Gata6*-induced cells still up-regulated endogenous *Gata6*, *Sox17*, *Gata4*, *Lama1*, *Col4a1*, and *Sparc* and down-regulated *Sox2* and *Esrrb* (Fig. 3E). This suggests that *Gata6* induction bypasses a possible requirement for *Oct4* in reprogramming mES cells to iXEN cells in vitro. To further confirm this, we used an *Oct4* conditional knockout mES cell line that induces trophectoderm differentiation following doxycycline-dependent loss of *Oct4* (Niwa et al. 2000; data not shown). We used a lentivirus to overexpress the human *GATA6* gene downstream from an *EF1a* promoter, which we confirmed successfully reprograms wild-type mES cells to iXEN cells (Supplemental Fig. S2D,E), similar to the doxycycline-inducible system. When we overexpressed *GATA6* in the *Oct4*-null cells, we observed the emergence of XEN-like cells (Fig. 3G), consistent with the *Pou5f1* knockdown cells. Western blot analysis confirmed that *Oct4* protein was undetectable following 12 h of doxycycline treatment (Fig. 3H).

To determine whether *Gata6*-induced reprogramming is dependent on the availability of endogenous *Fgf4*, we used site-specific recombination to integrate our inducible *Gata6* transgene into *Fgf4*^{-/-} mES cell lines (Cho et al. 2012; Kang et al. 2013). To eliminate the possibility of signaling from exogenous FGFs, we initially grew the *Fgf4*^{-/-} mES cells for three passages in serum-free medium in the presence of an Erk and Gsk3 inhibitor together with LIF (2i+LIF), as had been previously described (Ying et al. 2008). Interestingly, *Gata6* induction in *Fgf4*^{-/-} mES cells in basal serum-free medium in the absence of 2i+LIF or exogenous FGFs resulted in iXEN cell reprogramming and the up-regulation of *Gata4*, *Gata6*, *Sox7*, and *Sox17* (Fig. 3I,J), consistent with recent observations in mES cells transiently transfected with *Gata6* (Kang et al. 2013). Significantly, we also found that *Oct4*, *Sox2*, and *Nanog* were down-regulated independently of endogenous *Fgf4* following *Gata6* induction (Fig. 3J). To investigate the initial response to reprogramming, we analyzed the *Fgf4*^{-/-} *Gata6*-induced cells at defined time points between 12 and 144 h of induction by qRT-PCR (Supplemental Fig. S2F). These cells exhibited similar expression dynamics for pluripotency gene down-regulation and ExEn gene up-regulation compared with *Fgf4*^{+/+} *Gata6*-induced cells (Fig. 3B) or *Fgf4*^{-/-} *Gata6*-induced cells treated with exogenous FGF and heparin (Supplemental Fig. S2F). *Fgf4*^{-/-} iXEN cell lines were maintained for >10 passages in the absence of exogenous *Gata6* without loss of gene expression (Supplemental Fig. S2G) or iXEN cell morphology (Fig. 3I), demonstrating that there appears to be no requirement for a feedback loop up-regulating *Fgf4* to reinforce *Gata6*-mediated reprogramming. Moreover, given the absence of phosphorylated Erk (Fig. 3J), it is unlikely that Erk signaling is required. In all, we found that neither *Fgf4* nor *Oct4* is required for *Gata6*-mediated reprogramming of mES cells to iXEN cells.




Figure 3. *Gata6* induction results in dynamic changes in cell morphology and gene expression even in the absence of Oct4 and *Fgf4*. (A) Representative phase-contrast images of *Gata6*-overexpressing mES cells at defined time points from 0 to 144 h of doxycycline treatment. Bars, 100 μ m. (B) qRT-PCR analysis for selected pluripotency and endoderm transcripts in *Gata6*-overexpressing mES cells between 0 and 144 h of doxycycline induction. Relative expression is reflected as fold difference over uninduced mES cells normalized to *Gapdh*. Data are mean \pm SEM of three biological replicates. (C) Western blot for selected proteins in *Gata6*-overexpressing cells from 0 to 144 h of doxycycline induction. A representative Actin loading control is included as a reference. Endogenous (endo) and exogenous (exo) Gata6 bands are indicated. (D) Western blot for selected proteins in *Sox17*-overexpressing cells from 0 to 144 h of doxycycline induction. A representative Actin loading control is included as a reference. (E) qRT-PCR analysis for selected pluripotency and endoderm transcripts following 72 h of shRNA knockdown of *Pou5f1* during *Gata6* induction compared with scrambled control shRNA. Data are mean \pm SEM of five distinct shRNA constructs and two biological replicates. (***) $P < 0.001$. (F) Western blot for selected proteins in *Pou5f1* knockdown cells at the time points indicated. A representative Actin loading control is included as a reference. (G) Phase-contrast images of Oct4 conditional knockout cells following 6 d in the absence or presence of exogenous *Gata6* induction. Bars, 20 μ m. (H) Western blot for Oct4 protein in Oct4 conditional knockout cells at the time points indicated in the presence or absence of exogenous HA-tagged GATA6. A representative Actin loading control is included as a reference. (I) Phase-contrast image of stable *Fgf4*^{-/-} iXEN cells. Bars, 20 μ m. (J) Western blot for selected proteins in *Fgf4*-null mES cells following 6 d of *Gata6* induction in the absence or presence of *Fgf4* (F) and heparin (H). A representative Actin loading control is included as a reference.

Gata6 directly regulates multiple components of the pluripotency gene regulatory network as well as ExEn genes

To characterize the global transcriptional profile during *Gata6*-mediated reprogramming, we performed microarray analysis at defined time points from 12 to 144 h after induction. We included untreated mES cells to reflect the initial pluripotent state and eXEN cells as a reference for ExEn gene expression. Additionally, we included *Sox7*-expressing cells at 144 h after induction to compare their gene expression with *Gata6*-induced cells. To investigate gene expression dynamics, we performed K-means clustering on the scaled microarray data to group differentially expressed genes over the time course into 50 clusters (Fig. 4A; Supplemental Fig. S4).

We found that a number of functionally significant pluripotency-associated genes were rapidly and persistently down-regulated within 12 h of *Gata6* induction, including *Nanog*, *Sox2*, *Nr5a2*, *Klf2*, and *Nodal* (cluster 25) (Fig. 4A; Supplemental Fig. S4; Supplemental Table S1). Additional genes, including *Esrrb*, *Dazl*, *Dlk1*, *Ecsit*, and *Jarid1b* (cluster 29), were more gradually down-regulated over the time course compared with cluster 25. *Pou5f1*, *Lefty1*, *Dppa4*, and *Dppa2* (cluster 18) were more persistently expressed and eventually down-regulated, suggesting step-wise down-regulation of various nodes of the pluripotency gene regulatory network.

Gata6 induction also up-regulated the expression of several ExEn transcription factors, cell surface proteins, and basement membrane components in a step-wise manner (Fig. 4A; Supplemental Fig. S4; Supplemental Table S1). Initial up-regulation of *Gata6*, *Sox17*, *Sox7*, *Foxa1*, *Foxa2*, and *Pdgfra* (cluster 15) was followed by up-regulation of *Gata4*, *Hnf1b*, *Hnf4a*, and the key cell surface and basement membrane components *Dab2* and *Lama1* (cluster 39), which are thought to confer an adherence difference to PrE cells (Gerbe et al. 2008; Niakan et al. 2010; Artus et al. 2011). Additional basement membrane components and ExEn genes, including *Lamb2*, *Col4a1*, *Cited1*, and *Braf* (cluster 38), were up-regulated later in the time course. We did not identify key markers of ectodermal (*Nestin*, *Pax6*, *Sox1*, and *Sox3*) or mesodermal (*Flk1*, *Hand1*, *Mixl1*, *Nkx2.5*, and *T*) lineages within our microarray data set, suggesting that *Gata6* is specifically inducing an endoderm fate. In contrast, *Sox7*-expressing cells after 144 h of induction largely retained gene expression patterns similar to mES cells (Fig. 4A; Supplemental Fig. S4). Importantly, while *Sox7*-expressing cells have up-regulated some genes associated with XEN cell function, such as *Sall4* (cluster 33) (Lim et al. 2008), as before, they maintained expression of pluripotency factors (clusters 18, 25, and 29) and did not up-regulate endoderm-associated genes and basement membrane proteins to the same extent as *Gata6*-induced cells (clusters 15, 28, and 39).

Given the rapid changes in gene expression dynamics observed in our microarray analysis, we hypothesized that *Gata6* may directly regulate both pluripotency and ExEn genes. We performed ChIP followed by high-throughput sequencing (ChIP-seq) analysis of *Gata6* bind-

ing after 36 h of induction in order to capture both positive and negative gene regulatory dynamics as observed in our Western blot and qRT-PCR analyses (Fig. 3B,C). We identified 12,632 *Gata6*-bound regions enriched over the input control that were common between three biological replicates, with a false discovery rate (FDR) of <0.01% (Supplemental Table S2). We carried out de novo motif analysis on the top 500 most significant *Gata6*-bound regions and, as expected, identified the canonical GATA motif as the most highly enriched (Fig. 4B). We determined the binding distribution of *Gata6* throughout the genome and found significant enrichment <1000 base pairs (bp) upstream of gene promoters compared with the whole genome (P -value $\leq 3.7 \times 10^{-65}$). This is in contrast to *Gata6* binding downstream from genes, which has no significant difference compared with the genome (P -value ≤ 0.277) (Fig. 4C).

Importantly, we found *Gata6* binding enrichment at genes encoding multiple components of the pluripotency regulatory network, such as *Esrrb*, *Lefty1*, *Nr5a2*, *Nanog*, and *Pou5f1*, whose expression is down-regulated during reprogramming (Fig. 4D; Supplemental Fig. S5; Supplemental Table S2). *Gata6* was also enriched at a number of rapidly up-regulated ExEn-associated genes such as *Gata4* and *Pdgfra* (Fig. 4D; Supplemental Table S2), further suggesting that *Gata6* directly regulates both pluripotency and ExEn genes. Intriguingly, the GATA motifs within these regions share a high degree of sequence conservation between placental mammals in some but not all cases. We also identified *Gata6* enrichment upstream of *Fgfr2*, suggesting that *Gata6* may be directly regulating FGF signaling (Supplemental Fig. S5; Supplemental Table S2).

To relate *Gata6* binding to global gene expression dynamics, we compared the ChIP-seq analysis with our microarray cluster data set to identify the subset of *Gata6*-bound genes that were dynamically regulated over the microarray time course. We then performed gene ontology (GO) analysis comparing the *Gata6*-bound subset with the total microarray data set using the GOrilla analysis tool (Eden et al. 2009). *Gata6*-bound dynamically regulated genes were associated with signal transduction and regulation, DNA binding and transcriptional regulation, cell adhesion and migration, and stem cell maintenance (Supplemental Table S3). To investigate whether particular gene expression patterns correlated with GO, we identified a number of clusters that were continuously up-regulated or down-regulated over the *Gata6* induction time course and compared their GO term enrichment patterns. Down-regulated genes (clusters 3, 6, 9, 18, 19, 20, 23, 24, 25, 29, 34, and 46) were associated with protein binding, sequence-specific DNA binding, and biosynthetic processes (Supplemental Table S3). In contrast, genes that were continuously up-regulated (clusters 11, 15, 30, 38, 39, 40, and 47) were enriched for membrane components, endoderm formation, and protein glycosylation (Supplemental Table S3).

Importantly, our ChIP-seq and time-course transcriptome analysis revealed genes whose expression is also rapidly down-regulated and that cluster with known pluripotency factors. Given that *Gata6* directly regulates a




Figure 4. Gata6 enrichment near both pluripotency and endoderm genes. (A) Line plots of selected up-regulated or down-regulated clusters that contain key pluripotency or endoderm genes. Plots are based on mean scaled expression values from microarray analysis of *Gata6*-overexpressing cells from 12 to 144 h of doxycycline treatment. Uninduced mESC cells, eXEN cells, and *Sox7*-overexpressing cells after 144 h of doxycycline treatment were also included. Genes were grouped into 50 clusters using K-means clustering according to normalized gene expression values scaled across time points. The trajectories of scaled expression values for individual genes in each cluster across time are shown as gray lines, while the purple lines correspond to the cluster mean. (B) MEME *de novo* motif analysis of the top *Gata6*-bound regions following ChIP-seq (ChIP followed by high-throughput sequencing) analysis. (C) Comparison of *Gata6*-binding distribution (light blue) at selected regions relative to the genomic average (dark blue). (***) $P < 0.001$. (D) ChIP-seq binding profiles showing *Gata6* enrichment near pluripotency factors *Lefty1* and *Esrrb* and endoderm genes *Gata4* and *Pdgfra* (dark green). The input control profile (IP) is included for comparison (light green). Representative ChIP-seq binding profile of three biological replicates.

number of known pluripotency factors, these additional genes may also function to maintain pluripotency. One such candidate is *Etv5* (cluster 25), whose expression has also been associated with mES cells (Zhou et al. 2007), but whose function has not yet been tested in this context. Consequently, our work may provide a useful resource to identify putative pluripotency or, conversely, endoderm factors. However, the absence of *Gata6* enrichment near *Sox2*, whose expression is also rapidly down-regulated, may suggest indirect repression, possibly due to destabilizing alternative nodes of the pluripotency regulatory network. Alternatively, *Gata6* may function as a repressor via a binding site located further away.

Gata6 shares common gene targets and binding sites with pluripotency factors

We next sought to determine whether *Gata6* shares common gene targets and binding sites with pluripotency factors, which would suggest competition for pluripotency or ExEn target gene regulation. Using spatial heat map analysis, we compared *Gata6*-bound loci identified in our ChIP-seq analysis with published genome-wide occupancy of *Oct4*, *Sox2*, *Nanog*, *Klf4*, and *Esrrb* in mES cells (Fig. 5A; http://bioinformatics.cscr.cam.ac.uk/ES_Cell_ChIP-seq_compendium.html; Martello et al. 2012). We also investigated overlap between *Gata6* and pluripotency factor gene targets (Fig. 5B).

We found that *Gata6*-bound loci directly overlapped with 136 *Oct4*, 190 *Nanog*, 390 *Klf4*, or 188 *Sox2* gene loci (Fig. 5A). Intriguingly, some of these sites were present near pluripotency genes, including *Lefty1* (Supplemental Fig. S5), suggesting that *Gata6* may directly compete with pluripotency factors to antagonize the regulation of some common gene targets. Interestingly, we identified common loci at the distal enhancers of *Pou5f1* and *Nanog* (Fig. 5C), which are known to be relevant for pluripotency regulation (Kagey et al. 2010). However, these sites form a small proportion of the total *Gata6*-bound loci. We found more extensive overlap between *Gata6* and *Esrrb* (671 overlapping gene loci) (Fig. 5A), and shared loci were present in both pluripotency and ExEn genes (Fig. 5C). Notably, *Gata6* and *Esrrb* were enriched at a common locus upstream of the endogenous *Gata6* promoter, suggesting possible competition for regulation.

We also observed that genes such as *Nr5a2* and *Esrrb* were bound by both *Gata6* and one or more of the pluripotency factors but that these sites did not directly overlap (Supplemental Fig. S5). When we examined the shared gene target data set (Fig. 5B; Supplemental Table S4), we found that out of 6192 identified *Gata6* target genes, 4195 were also targets of *Esrrb*, 2815 were also targets of *Klf4*, 1364 were also targets of *Sox2*, 1616 were also targets of *Nanog*, and 1104 were also targets of *Oct4* (Fig. 5B), suggesting that *Gata6* may regulate the pluripotency network both directly and indirectly. Curiously, we identified several key ExEn genes within the list of *Gata6* gene targets shared with *Esrrb*, including *Gata6*, *Gata4*, *Sox17*, *Col4a1*, *Fgfr2*, *Pdgfra*, and *Sox7* (Supplemental Fig. S5; Supplemental Table S4). In contrast, most of these key

ExEn genes were not identified among the *Nanog*, *Oct4*, and *Sox2* target gene sets. Previous studies have shown that, in addition to its function in pluripotent cells downstream from *Nanog* (Festuccia et al. 2012), *Esrrb* knockdown or overexpression affects endoderm gene expression (Ivanova et al. 2006; Loh et al. 2006; Uranishi et al. 2013). However, when we overexpressed an *Esrrb* transgene (van den Berg et al. 2008; Uranishi et al. 2013) concomitant with doxycycline-induced *Gata6* expression, this did not prevent the down-regulation of *Nanog* expression (Supplemental Fig. S6A) or iXEN-like cell differentiation (data not shown). Moreover, by immunofluorescence analysis, we found that in mouse preimplantation embryos, *Esrrb* and *Gata6* expression was coincident even after down-regulation of *Nanog* in *Gata6*-high PrE cells (Supplemental Fig. S6B). This suggests that *Esrrb* may not function to inhibit ExEn differentiation in this context or that alternative factors may be required in tandem to block the endoderm-promoting effect of *Gata6*. Knockdown of additional pluripotency factors such as *Prdm14* and *Nr5a2* has been shown to up-regulate ExEn genes (Ma et al. 2011; McDonald et al. 2014). Indeed, when we compared *Gata6*-bound loci with those occupied by *Prdm14* in mES cells, we identified extensive overlap of common gene targets (Fig. 5B; Supplemental Table S4) as well as overlapping binding sites (843 overlapping gene loci) (Fig. 5A,C). Consequently, the greater degree of overlap with *Gata6*-bound sites may reflect the dual role of both *Gata6* and a pluripotency factor subset in driving their respective cell fates.

To investigate whether the binding sites that we identified during *Gata6* reprogramming are maintained in eXEN cells, we performed ChIP-seq analysis of *Gata6* occupancy in eXEN cell lines (Supplemental Table S5,S6). Of the 927 *Gata6* gene targets in eXEN cells, 504 genes were also targets of *Gata6* at the 36-h post-induction time point (Supplemental Table S4). This includes *Gata6* endoderm target genes such as *Gata4*, *Gata6*, *Sox7*, and *Lamc1*. Interestingly, we did not detect enrichment of *Gata6* binding near many of the pluripotency target genes that we identified at the 36-h post-induction time point, with the notable exception of *Nr5a2*. This demonstrates that *Gata6* binding in eXEN cells is distinct compared with cells in transition and suggests that there may not be a requirement for *Gata6* to actively repress pluripotency factor expression long after they are down-regulated.

Gata6 initiates an ExEn program in differentiated cells and hES cells

We also sought to determine whether *Gata6* could reprogram cells other than mES cells. To investigate this, we used a pure culture of stable neural stem cells that were previously shown to generate functional neurons that contribute to the adult brain in mouse chimeras, without the formation of teratomas (Conti et al. 2005). This avoids the possibility of residual pluripotent or partially differentiated cells, which may be present at early stages of directed differentiation protocols. We expressed *GATA6* in neural stem cells by lentiviral transduction in neural basal medium and evaluated the identity of the cells 20 d after




Figure 5. Gata6 binds to loci occupied by pluripotency factors in mES cells. (A) Density heat maps of Gata6-binding peak intensity after 36 h of Gata6 induction, indicating direct overlap with Nanog, Oct4, Sox2, Klf4, Esrrb, or Prdm14 binding in mES cells within a 10-kb window centered on the transcription start site (TSS). Data for Nanog, Oct4, Sox2, Klf4, Esrrb, and Prdm14 were obtained from the Mouse ES Cell ChIP-Seq Compendium (http://bioinformatics.cscr.cam.ac.uk/ES_Cell_ChIP-seq_compendium.html; Martello et al. 2012). (B) Venn diagram indicating the overlap of Gata6-bound genes during reprogramming compared with genes previously shown to be bound by Oct4, Sox2, Klf4, Esrrb, or Prdm14 in mES cells. (C) Binding profiles at the *Pou5f1*, *Nanog*, *Gata6*, and *Foxa2* loci for Gata6 and the input control during reprogramming compared with Nanog, Oct4, Sox2, Klf4, Esrrb, or Prdm14 in mES cells.

induction (Fig. 6A). Despite their morphological resemblance to neurons, immunofluorescence analysis confirms robust induction of Gata6, Sox7, and Sox17 proteins

(Fig. 6B) in the GATA6-overexpressing cells. Importantly, the preinduced cells lacked detectable expression of Oct4 and Nanog (Conti et al. 2005), which we confirmed was




Figure 6. Gata6 initiates an ExEn program in mouse neural stem cells and hES cells. (A) Phase-contrast images of uninduced or GATA6-induced mouse neural stem cells. Bars, 50 μ m. (B) Immunofluorescence analysis for Sox7, Sox17, Gata6, or Nestin (green) and Oct4 or Nanog (red) with DAPI (blue) merge in GATA6-induced mouse neural stem cells after 20 d of induction. Bars, 50 μ m. (C) qRT-PCR analysis of mouse neural stem cells for HA-tagged exogenous GATA6 and selected endoderm transcripts (*Gata6*, *Sox7*, *Sox17*, *Col4a1*, *Lama1*, *Dab2*, and *Foxa3*) 20 d following transduction. Data are mean \pm SEM of two replicates. (D) Immunofluorescence analysis for OCT4 or GATA6 (green) and SOX17 with DAPI (blue) merge in hES and human iPS (hiPS) cells in pluripotent culture conditions. Bars, 50 μ m. (E) Representative phase-contrast images of GATA6-transduced hES cells 6 d after GATA6 induction compared with uninduced controls in pluripotency (mTeSR) or differentiation (KSR) medium. Bars, 50 μ m. (F) Principal component analysis using RPKM (reads per kilobase per million mapped reads)-normalized RNA sequencing (RNA-seq) data from biological replicates of uninduced and GATA6-induced (+G) cells in KSR (K) or mTeSR (M) medium. (G) Heat maps showing the hierarchical clustering of uninduced and GATA6-induced (+G) cells in KSR (K) or mTeSR (M) medium using RPKM-normalized RNA-seq data. Expression levels plotted on a high-to-low scale (purple–white–green). (H) DESeq analysis indicating genes significantly differentially expressed in the uninduced control versus GATA6-induced cells in both the KSR and mTeSR conditions. The median gene expression and log₂ fold change (FC) difference in expression are noted. (I) qRT-PCR analysis of H1 and H9 hES cells for HA-tagged exogenous GATA6 expression and selected pluripotency (*POU5F1*, *NANOG*, and *SOX2*) and endoderm (*GATA6*, *SOX7*, *SOX17*, and *FOXA2*) transcripts 6 d following transduction. Data are mean \pm SEM of two to three replicates. (J) Immunofluorescence analysis of OCT4, NANOG, GATA4, SOX7, SOX17, and GATA6 (all green) and HA (red) with DAPI (blue) merge in GATA6-induced H9 hES cells 5 d following doxycycline treatment. Bars, 50 μ m.

also undetectable in the GATA6-induced cells (Fig. 6B). We observed low levels of detectable Nestin expression in these cells (Fig. 6B), suggesting that an additional time interval may be required to stabilize the XEN cell program and fully overcome the neural stem cell state. qRT-PCR analysis confirmed that the *GATA6*-induced cells up-regulated the XEN factors *Gata6*, *Sox7*, *Sox17*, *Col4a1*, *Lama1*, *Dab2*, and *Foxa3* (Fig. 6C). In all, the ability of *Gata6* to promote reprogramming to iXEN-like cells does not appear to be restricted solely to mES cells.

We next sought to investigate the broader reprogramming potential of *Gata6*. We observed SOX17 and GATA6-co-expressing cells within hES and iPS cell cultures maintained in pluripotency conditions (Fig. 6D). This is reminiscent of the Sox17-expressing XEN-committed cells that we observed previously in mES cell cultures (Niakan et al. 2010) and suggests that hES cell may also have the potential to be converted to XEN cell lines. We then transduced hES cells in both pluripotency (mTeSR) and differentiation-promoting (KSR) conditions to determine whether *GATA6* expression is sufficient to drive iXEN cell reprogramming from hES cells. Significantly, as stable human XEN cell lines have yet to be established, no morphological benchmark exists.

GATA6-transduced hES cells exhibited a morphology that is distinct from hES cell colonies even in conditions that otherwise favor their pluripotency (Fig. 6E). We next compared the global transcriptional profile of *GATA6*-transduced versus untransduced hES cells by RNA sequencing (RNA-seq). We initially used principal component analysis (PCA), which demonstrates that the *GATA6*-induced samples cluster together irrespective of the basal medium and were transcriptionally distinct from untransduced cells (Fig. 6F). We also used an independent method of hierarchical clustering, which again demonstrates that, independent of the basal medium, the *GATA6*-induced cells cluster together and are distinct from the untransduced cells (Fig. 6G). Notably, *GATA6*-transduced hES cells up-regulated a number of extraembryonic and/or pan-endoderm factors, including *GATA6*, *GATA4*, *SOX17*, *SOX7*, *FOXA2*, *PDGFRA*, *COL4A1*, *COL4A2*, *LAMA1*, *HNF4a*, *DAB2*, and *SPARC* (Fig. 6G, H; Supplemental Tables S5, S6). Significantly, we confirmed that the *GATA6*-induced cells down-regulated pluripotency factors, including *NANOG*, *POU5F1*, *SOX2*, *PRDM14*, *FGF2*, *FOXD3*, *DPPA4*, and *ZSCAN10*. qRT-PCR analysis confirmed the up-regulation of endogenous *GATA6*, *SOX17*, *SOX7*, and *FOXA2* transcripts between 10-fold and 1000-fold and the down-regulation of the expression of *NANOG*, *SOX2*, and *POU5F1* (Fig. 6I). However, expression of genes associated with alternative lineages, including *FLK4*, *TBX3*, *CDX2*, *GATA3*, *SMAD6*, *EOMES*, *HAND1*, and *TUBB3*, suggests that the *GATA6*-induced hES cells may not be fully reprogrammed to stable iXEN cells (Fig. 6I). Moreover, although we clonally passaged the *GATA6*-transduced hES cells more than three times and they maintained their morphology for >1 mo, they could not be maintained indefinitely, suggesting that alternative conditions or factors may be required to derive stable human iXEN cells.

In tandem, we engineered *GATA6* doxycycline-inducible hES cells by lentiviral transduction of a tetracycline/doxycycline-inducible HA-tagged *GATA6* transgene. hES cells in pluripotency medium treated with doxycycline exhibited a morphological switch similar to the *GATA6* virally transduced cells (Fig. 6E; data not shown). Importantly, the *GATA6* doxycycline-induced cells have down-regulated OCT4 and NANOG in most cells (Fig. 6J). Moreover, the induced cells have up-regulated the expression of the HA-tagged *GATA6*, *SOX7*, *SOX17*, and *GATA4* proteins (Fig. 6J). While exogenous *GATA6* initiated reprogramming of hES cells to iXEN-like cells, the heterogeneity in endoderm protein induction suggests that an additional time interval, culture condition, or factor may be needed to generate self-renewing human iXEN cell lines. Nevertheless, this suggests that *GATA6/Gata6* is sufficient to overcome a number of distinct cell states to drive iXEN-like cell reprogramming.

Discussion

We show that *Gata6* functions to reprogram a number of cell types into iXEN-like cells. In the context of mES cell reprogramming, it does so by rapid and potentially direct repression of the pluripotency gene regulatory network coupled with activation of an endoderm gene program. What distinguishes *Gata6* from other endoderm transcription factors that we tested is the speed with which it acts to induce a cell fate switch in the absence of selection. Indeed, most reprogramming, including iPS cells, can take several days of selective culture. As the induction of *Sox17* takes >2 wk to down-regulate pluripotency (McDonald et al. 2014), this suggests that indirect mechanisms eventually lead to XEN conversion, perhaps via *Gata6*. It would therefore be interesting to determine whether *Sox17* can induce XEN reprogramming in the absence of *Gata6*. This seems unlikely given that *Gata6* mutant mES cells fail to initiate cXEN cell conversion in growth factor-mediated conditions, in contrast to *Sox17* mutant ES cells that initiate but fail to maintain cXEN cells (Cho et al. 2012).

Investigating the mechanisms of *Gata6*-mediated iXEN cell reprogramming may provide insights into the genetic hierarchy involved in ExEn development in vivo (Fig. 7). In mouse embryos, *Gata6* expression is initiated in the absence of Oct4/Nanog-mediated Fgf4 signaling, but downstream *Gata4* and *Sox17* expression is compromised (Frankenberg et al. 2011; Frum et al. 2013; Le Bin et al. 2014; Schrode et al. 2014). Our results suggest that induction of *Gata6* can up-regulate *Gata4* and *Sox17* in the absence of Fgf4 in vitro, consistent with recent findings (Kang et al. 2013). Ectopic expression of *Gata6* has also been shown to restore endoderm differentiation in ES cells lacking the FGF signaling adaptor Grb2 (Wang et al. 2011). We also show that *Gata6* positively regulates itself as well as *Fgfr2*, *Gata4*, and *Sox17*. This suggests that, in the embryo, *Gata6* may require a feedback loop via Fgf4/Fgfr2 signaling to reinforce its own expression to achieve a certain threshold, which subsequently triggers the expression of *Gata4* and *Sox17*. This is consistent with the insufficiency




Figure 7. Model of the hierarchy of gene activity during iXEN reprogramming. Here we show that the requirement for Oct4/Nanog during development to reinforce PrE development via FGF signaling (A) can be bypassed in vitro with the induction of Gata6 (B), which can potently induce mES-to-iXEN cell reprogramming in the absence of Oct4 or Fgf4. Gata6 can bind to and rapidly induce the expression of downstream elements of an ExEn gene regulatory network (including Gata4 and Sox17). Gata6 can also simultaneously inhibit the expression of core and peripheral components of the pluripotency gene regulatory network. In all, the dual function of Gata6 as a repressor and activator potently drives mES-to-iXEN cell reprogramming.

of exogenous Fgf4 to restore Sox17 expression in Gata6 mutant embryos (Schrode et al. 2014). This may also explain the colocalization of Nanog and Gata6 in vivo, whereby a threshold of Gata6 expression needs to be reached in order to overcome pluripotency and specify the PrE. Gata6 overexpression in vitro likely exceeds this threshold, thereby leading to down-regulation of pluripotency and up-regulation of ExEn genes, thus allowing iXEN reprogramming to proceed in the absence of Fgf4. Inducing high levels of Gata6 expression in Fgf4 mutant mouse embryos would be one approach to test this hypothesis. Alternatively, Gata6 levels could be fine-tuned in vitro to determine whether Gata6-low Fgf4 mutant cells fail to induce Gata4 and Sox17. Lowering the dose of doxycycline in our inducible system has been shown to reduce the penetrance and therefore the percentage of cells inducing expression rather than the quantitative levels within a given cell (Beard et al. 2006). This apparent discrepancy between the in vivo requirement for Fgf4 signaling in the PrE may also be the result of the presence of signaling pathways that facilitate the destabilization of pluripotency in vitro or differences between ES cells and early inner cell mass cells within the blastocyst (Boroviak et al. 2014).

One of the advantages of our analysis of global Gata6 binding during the transition of mES cells to iXEN cells is that it revealed that Gata6 may function simultaneously as both an activator and repressor of genes during reprogramming but not in eXEN cells. It has been suggested that other GATA transcription factors, such as Gata1, also have a dual activator and repressor role (Yu et al. 2009). However, it is unclear precisely how Gata6 functions to regulate both sets of target genes and whether cofactors, chromatin, or other epigenetic mechanisms may influence this decision. The analysis of sequences surrounding Gata6-bound loci has not yet revealed motifs that consistently distinguish Gata6-bound down-regulated genes from Gata6-bound up-regulated genes (data not

shown). Interestingly, we identified Gata6 binding upstream of the *Nanog* promoter and within an intron of *Esrrb*. One possibility is to use the emerging RNA-guided CRISPR-Cas nuclease system (Cong et al. 2013; Mali et al. 2013) to mutagenize these endogenous sites to interrogate not only these putative Gata6 regulatory loci but also those of other pluripotency factors and endoderm targets.

Remarkably, Gata6 drives iXEN-like cells from mouse neural stem cells, showing that it is a broad inducer of reprogramming. It is surprising that Gata6 can overcome intrinsic programs within these cell types. As mES cells have a characteristic open chromatin state, Gata6 may have fewer roadblocks to directly bind to regulatory elements to control gene expression. However, in neural cells, it would be surprising if all endoderm target genes remained readily accessible for Gata6 direct regulation. Therefore, one possibility is that Gata6 may be functioning as a pioneering transcription factor in these contexts, exposing otherwise closed heterochromatic regions, as has been shown for FoxA2 and Gata4 (Zaret and Carroll 2011). Given the pleiotropic function of Gata6 in promoting endoderm- and mesoderm-derived cell types, it is also surprising that there is only one reprogramming outcome. Further characterization of Gata6-mediated reprogramming in several cellular contexts would allow interrogation of the relationship between transcription factors, signaling, and epigenetics in driving cell state transitions.

Induction of *SOX7* or *SOX17* has been previously reported to drive XEN-like or definitive endoderm-like cells, respectively, from hES cells (Seguin et al. 2008). However, these cells cannot be maintained indefinitely in culture, and, significantly, *SOX7*- or *SOX17*-expressing hES cells retain pluripotency gene expression (Seguin et al. 2008). GATA6 induction is able to both inhibit the pluripotency program and promote ExEn gene expression, suggesting that, in this context, stable human XEN cells may have the potential to be established. Given the potency of the doxycycline-inducible system in initiating iXEN reprogramming in hES cells, it would be interesting to determine whether alternative culture conditions could effectively capture stable human iXEN cells. Recent transcriptomic analysis of human embryos (Yan et al. 2013) may lead to the identification of signaling pathways that may be important to stabilize GATA6-induced human XEN cell lines. Together, this demonstrates that Gata6 is a versatile and potent reprogramming factor that can act alone to drive a cell fate switch from diverse cell types.

Materials and methods

Culture conditions for pluripotent stem cell lines and transcription factor induction

mES cells were maintained on mouse embryonic fibroblast (MEF)-coated pregelatinized tissue culture plates (Corning) in serum and 10 ng/mL LIF. Additional medium components are listed in Supplemental Table S4. For details of the generation of inducible mES cell lines, see the Supplemental Material. Induction of mES cells was performed in pluripotency maintenance medium using doxycycline at a final concentration of 1 μ g/mL.

Doxycycline (1 $\mu\text{g}/\text{mL}$) was also used to generate Oct4-null cells from ZHBTc4 mES cells (Niwa et al. 2000). H9 and H1 hES cells (WiCell) were cultured in mTeSR1 (Stem Cell Technologies) on Matrigel (BD Biosciences)-coated dishes. Lentiviral packaging was performed in HEK293T cells using Lipofectamine 3000 (Life Technologies) cotransfection of a plasmid containing an *EF1 α* promoter driving the expression of human HA-tagged GATA6 and the puromycin resistance gene (AMSBio) together with packaging plasmids. Forty-eight hours after lentiviral transduction, cells were selected using 1 $\mu\text{g}/\text{mL}$ puromycin (Sigma).

qRT-PCR

RNA was isolated using TRI reagent (Sigma) and DNase I-treated (Ambion). cDNA was synthesized using a Maxima first strand cDNA synthesis kit (Fermentas). qRT-PCR was performed using Quantace Sensimix on an Applied Biosystems 7500 machine (Life Technologies Corporation). Primer pairs were previously published (Molkentin et al. 1997; Fujikura et al. 2002; Niwa et al. 2005; Brown et al. 2010a) or designed using Primer3 software. All primers are listed in Supplemental Table S6.

Immunohistochemistry and imaging

Samples were fixed in 4% paraformaldehyde for 1 h or overnight at 4°C, permeabilized with 0.5% Tween in 1 \times PBS for 20 min, and blocked with 10% FBS diluted in 0.1% Tween in 1 \times PBS for 1 h. Primary antibodies were diluted at 1:500 in blocking solution, and samples were incubated overnight at 4°C rotating. Secondary antibodies were diluted at 1:300 in blocking solution, and samples were incubated for 1 h at room temperature, washed, and covered with 0.1% Tween in 1 \times PBS containing DAPI VectaShield mounting medium (Vector Laboratories). A list of the antibodies used is in Supplemental Table S7. Images were taken on either an Olympus 1X71 microscope with Cell[^]F software (Olympus Corporation), a Zeiss Axiovert 200M microscope with AxioVision release 4.7 software (Carl Zeiss Ltd.), or a Leica SP5 inverted confocal microscope (Leica Microsystems Ltd).

Western blot analysis

Whole-cell protein was extracted with CelLytic M reagent (Sigma) supplemented with proteinase and phosphatase inhibitors (Roche). Thirty micrograms of protein per sample was resolved on 12% SDS-PAGE gels and transferred to PVDF membrane using a Bio-Rad Trans-Blot transfer system (Bio-Rad). Membranes were blocked in 5% skimmed milk or 5% BSA in TBS 0.1% Tween and incubated with primary antibody overnight at 4°C. Following washes in TBS 0.1% Tween, membranes were incubated with secondary antibody in 5% milk or 5% BSA for 1 h at room temperature. Proteins were visualized using the Pierce ECL Western blotting substrate (Thermo). Antibodies used are listed in Supplemental Table S7.

Microarray analysis

Total RNA was isolated as above and DNase I-treated (Ambion). RNA quality was assessed on a eukaryote total RNA Nano series II (Agilent Technologies) and then processed on an Agilent 2100 Bioanalyzer using the RNA electrophoresis program. All RNA samples were amplified using the Total Prep 96 RNA amplification kit (Ambion). Samples were hybridized to Illumina MouseWG-6_V2 expression BeadChip arrays (Illumina, Inc.) Biological triplicates were collected for each sample. Computational analysis details are included in the Supplemental Material.

ChIP-seq

Gata6-inducible mES cells were seeded at 1×10^4 cells per square centimeter and treated with 1 $\mu\text{g}/\text{mL}$ doxycycline for 36 h prior to harvesting. Immunoprecipitation was performed on 1×10^7 to 2×10^7 cells as described (Vokes et al. 2007) for three biological replicates versus input samples. Sonication was performed using a Misonix 4000 (28 cycles of 15 sec on and 45 sec off at an intensity of 70%) with a microtip probe (Misonix). The antibodies used are listed in Supplemental Table S7. Libraries were prepared using the TruSeq ChIP sample preparation kit, and the resulting samples were sequenced using the Illumina Genome Analyzer II (Illumina). Data will be deposited into Gene Expression Omnibus and released immediately after publication (GSE69323). Computational analysis details are included in the Supplemental Material.

Acknowledgments

We thank James Turner and Tiago Faial for advice and critical reading of the manuscript. We thank Zachary Gaber and Francois Guillemot for the neural stem cell lines and media. We thank Lucas Baltussen and Sila Ultanir for the HEK293T cells. We are grateful to Abdul Sesay and Leena Bhaw-Rosun at the Francis Crick Institute High-Throughput Sequencing Facility for their assistance with RNA-seq and ChIP-seq. We are grateful to Sarah Johnson, Marta Miret, Nicolle Morey, and Lucia Goyeneche in the Procedural Services Section for their assistance with the chimera experiments. We thank Clare Wise at the Stem Cell Facility, Donald Bell, and members of the Confocal and Image Analysis Laboratory. We thank Rudolf Jaenisch for targeting vectors, Austin Smith for the neural stem cells and conditional Oct4 knockout mES cells, and Tadayuki Akagi for the Esrrb expression plasmid. H.J. is supported by National Institutes of Health grant R01HG006841 and Maryland Stem Cell Research Fund 2012-MSCRFE-0135-00. This work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK; the UK Medical Research Council (MC_UP_1202/9); and the Wellcome Trust. In addition, this research was supported by the March of Dimes Foundation (FY11-436) to K.K.N.

References

- Arman E, Haffner-Krausz R, Chen Y, Heath JK, Lonai P. 1998. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. *Proc Natl Acad Sci* **95**: 5082–5087.
- Artus J, Piliszek A, Hadjantonakis AK. 2011. The primitive endoderm lineage of the mouse blastocyst: sequential transcription factor activation and regulation of differentiation by Sox17. *Dev Biol* **350**: 393–404.
- Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R. 2006. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. *Genesis* **44**: 23–28.
- Boroviak T, Loos R, Bertone P, Smith A, Nichols J. 2014. The ability of inner-cell-mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. *Nat Cell Biol* **16**: 516–528.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* **122**: 947–956.
- Brown K, Doss MX, Legros S, Artus J, Hadjantonakis AK, Foley AC. 2010a. Extraembryonic endoderm (XEN) stem cells

- produce factors that activate heart formation. *PLoS One* **5**: e13446.
- Brown K, Legros S, Artus J, Doss MX, Khanin R, Hadjantonakis AK, Foley A. 2010b. A comparative analysis of extra-embryonic endoderm cell lines. *PLoS One* **5**: e12016.
- Capo-Chichi CD, Rula ME, Smedberg JL, Vanderveer L, Parmacek MS, Morrisey EE, Godwin AK, Xu XX. 2005. Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. *Dev Biol* **286**: 574–586.
- Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A. 2007. Nanog safeguards pluripotency and mediates germline development. *Nature* **450**: 1230–1234.
- Chazaud C, Yamanaka Y, Pawson T, Rossant J. 2006. Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the Grb2–MAPK pathway. *Dev Cell* **10**: 615–624.
- Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, Bachvarova RF, Darnell JE Jr. 1994. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. *Genes Dev* **8**: 2466–2477.
- Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, et al. 2008. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* **133**: 1106–1117.
- Cho LT, Wamaitha SE, Tsai IJ, Artus J, Sherwood RI, Pedersen RA, Hadjantonakis AK, Niakan KK. 2012. Conversion from mouse embryonic to extra-embryonic endoderm stem cells reveals distinct differentiation capacities of pluripotent stem cell states. *Development* **139**: 2866–2877.
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**: 819–823.
- Conti L, Pollard SM, Gorba T, Reitano E, Toselli M, Biella G, Sun Y, Sanzone S, Ying QL, Cattaneo E, et al. 2005. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. *PLoS Biol* **3**: e283.
- Davis RL, Weintraub H, Lassar AB. 1987. Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* **51**: 987–1000.
- Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. 2009. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. *BMC Bioinformatics* **10**: 48.
- Evans MJ, Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. *Nature* **292**: 154–156.
- Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, Goldfarb M. 1995. Requirement of FGF-4 for postimplantation mouse development. *Science* **267**: 246–249.
- Festuccia N, Osorno R, Halbritter F, Karwacki-Neisius V, Navarro P, Colby D, Wong F, Yates A, Tomlinson SR, Chambers I. 2012. Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells. *Cell Stem Cell* **11**: 477–490.
- Frankenberg S, Gerbe F, Bessonard S, Belville C, Pouchin P, Bardot O, Chazaud C. 2011. Primitive endoderm differentiates via a three-step mechanism involving Nanog and RTK signaling. *Dev Cell* **21**: 1005–1013.
- Frum T, Halbisen MA, Wang C, Amiri H, Robson P, Ralston A. 2013. Oct4 cell-autonomously promotes primitive endoderm development in the mouse blastocyst. *Dev Cell* **25**: 610–622.
- Fujikura J, Yamato E, Yonemura S, Hosoda K, Masui S, Nakao K, Miyazaki Ji J, Niwa H. 2002. Differentiation of embryonic stem cells is induced by GATA factors. *Genes Dev* **16**: 784–789.
- Futaki S, Hayashi Y, Emoto T, Weber CN, Sekiguchi K. 2004. Sox7 plays crucial roles in parietal endoderm differentiation in F9 embryonal carcinoma cells through regulating Gata-4 and Gata-6 expression. *Mol Cell Biol* **24**: 10492–10503.
- Gerbe F, Cox B, Rossant J, Chazaud C. 2008. Dynamic expression of Lrp2 pathway members reveals progressive epithelial differentiation of primitive endoderm in mouse blastocyst. *Dev Biol* **313**: 594–602.
- Grabarek JB, Zyzynska K, Saiz N, Piliszek A, Frankenberg S, Nichols J, Hadjantonakis AK, Plusa B. 2012. Differential plasticity of epiblast and primitive endoderm precursors within the ICM of the early mouse embryo. *Development* **139**: 129–139.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M, Nagy A. 1998. Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech Dev* **76**: 79–90.
- Hall J, Guo G, Wray J, Eyres I, Nichols J, Grotewold L, Morfopoulou S, Humphreys P, Mansfield W, Walker R, et al. 2009. Oct4 and Lf/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell* **5**: 597–609.
- Hochedlinger K, Yamada Y, Beard C, Jaenisch R. 2005. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* **121**: 465–477.
- Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR. 2006. Dissecting self-renewal in stem cells with RNA interference. *Nature* **442**: 533–538.
- Kaestner KH, Hiemisch H, Schutz G. 1998. Targeted disruption of the gene encoding hepatocyte nuclear factor 3 γ results in reduced transcription of hepatocyte-specific genes. *Mol Cell Biol* **18**: 4245–4251.
- Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier CC, Goossens J, Rahl PB, Levine SS, et al. 2010. Mediator and cohesin connect gene expression and chromatin architecture. *Nature* **467**: 430–435.
- Kang M, Piliszek A, Artus J, Hadjantonakis AK. 2013. FGF4 is required for lineage restriction and salt-and-pepper distribution of primitive endoderm factors but not their initial expression in the mouse. *Development* **140**: 267–279.
- Koutsourakis M, Langeveld A, Patient R, Beddington R, Grosveld F. 1999. The transcription factor GATA6 is essential for early extraembryonic development. *Development* **126**: 723–732.
- Kunath T, Arnaud D, Uy GD, Okamoto I, Chureau C, Yamanaka Y, Heard E, Gardner RL, Avner P, Rossant J. 2005. Imprinted X-inactivation in extra-embryonic endoderm cell lines from mouse blastocysts. *Development* **132**: 1649–1661.
- Le Bin GC, Munoz-Descalzo S, Kurowski A, Leitch H, Lou X, Mansfield W, Etienne-Dumeau C, Grabole N, Mulas C, Niwa H, et al. 2014. Oct4 is required for lineage priming in the developing inner cell mass of the mouse blastocyst. *Development* **141**: 1001–1010.
- Lim CY, Tam WL, Zhang J, Ang HS, Jia H, Lipovich L, Ng HH, Wei CL, Sung WK, Robson P, et al. 2008. Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. *Cell Stem Cell* **3**: 543–554.
- Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, et al. 2006. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* **38**: 431–440.
- Ma Z, Swigut T, Valouev A, Rada-Iglesias A, Wysocka J. 2011. Sequence-specific regulator Prdm14 safeguards mouse ESCs from entering extraembryonic endoderm fates. *Nat Struct Mol Biol* **18**: 120–127.

- Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. *Science* **339**: 823–826.
- Martello G, Sugimoto T, Diamanti E, Joshi A, Hannah R, Ohtsuka S, Gottgens B, Niwa H, Smith A. 2012. Esrrb is a pivotal target of the Gsk3/Tcf3 axis regulating embryonic stem cell self-renewal. *Cell Stem Cell* **11**: 491–504.
- Martin GR. 1981. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci* **78**: 7634–7638.
- McDonald AC, Biechele S, Rossant J, Stanford WL. 2014. Sox17-mediated XEN cell conversion identifies dynamic networks controlling cell-fate decisions in embryo-derived stem cells. *Cell Rep* **9**: 780–793.
- Molkentin JD, Lin Q, Duncan SA, Olson EN. 1997. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. *Genes Dev* **11**: 1061–1072.
- Morris SA, Teo RT, Li H, Robson P, Glover DM, Zernicka-Goetz M. 2010. Origin and formation of the first two distinct cell types of the inner cell mass in the mouse embryo. *Proc Natl Acad Sci* **107**: 6364–6369.
- Morrisey EE, Tang Z, Sigrist K, Lu MM, Jiang F, Ip HS, Parmacek MS. 1998. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. *Genes Dev* **12**: 3579–3590.
- Niakan KK, Ji H, Maehr R, Vokes SA, Rodolfa KT, Sherwood RI, Yamaki M, Dimos JT, Chen AE, Melton DA, et al. 2010. Sox17 promotes differentiation in mouse embryonic stem cells by directly regulating extraembryonic gene expression and indirectly antagonizing self-renewal. *Genes Dev* **24**: 312–326.
- Niakan KK, Schrode N, Cho LT, Hadjantonakis AK. 2013. Derivation of extraembryonic endoderm stem (XEN) cells from mouse embryos and embryonic stem cells. *Nat Protoc* **8**: 1028–1041.
- Niwa H, Miyazaki J, Smith AG. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* **24**: 372–376.
- Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R, Rossant J. 2005. Interaction between Oct3/4 and Cdx2 determines trophoblast differentiation. *Cell* **123**: 917–929.
- Niwa H, Ogawa K, Shimosato D, Adachi K. 2009. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. *Nature* **460**: 118–122.
- Plusa B, Piliszek A, Frankenberg S, Artus J, Hadjantonakis AK. 2008. Distinct sequential cell behaviours direct primitive endoderm formation in the mouse blastocyst. *Development* **135**: 3081–3091.
- Schrode N, Saiz N, Di Talia S, Hadjantonakis AK. 2014. GATA6 levels modulate primitive endoderm cell fate choice and timing in the mouse blastocyst. *Dev Cell* **29**: 454–467.
- Seguin CA, Draper JS, Nagy A, Rossant J. 2008. Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. *Cell Stem Cell* **3**: 182–195.
- Shimoda M, Kanai-Azuma M, Hara K, Miyazaki S, Kanai Y, Monden M, Miyazaki J. 2007. Sox17 plays a substantial role in late-stage differentiation of the extraembryonic endoderm in vitro. *J Cell Sci* **120**: 3859–3869.
- Shimosato D, Shiki M, Niwa H. 2007. Extra-embryonic endoderm cells derived from ES cells induced by GATA factors acquire the character of XEN cells. *BMC Dev Biol* **7**: 80.
- Soudais C, Bielinska M, Heikinheimo M, MacArthur CA, Narita N, Saffitz JE, Simon MC, Leiden JM, Wilson DB. 1995. Targeted mutagenesis of the transcription factor GATA-4 gene in mouse embryonic stem cells disrupts visceral endoderm differentiation in vitro. *Development* **121**: 3877–3888.
- Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**: 663–676.
- Uranishi K, Akagi T, Sun C, Koide H, Yokota T. 2013. Dax1 associates with Esrrb and regulates its function in embryonic stem cells. *Mol Cell Biol* **33**: 2056–2066.
- van den Berg DL, Zhang W, Yates A, Engelen E, Takacs K, Bezstarosti K, Demmers J, Chambers I, Poot RA. 2008. Estrogen-related receptor β interacts with Oct4 to positively regulate Nanog gene expression. *Mol Cell Biol* **28**: 5986–5995.
- Vokes SA, Ji H, McCuine S, Tenzen T, Giles S, Zhong S, Longabaugh WJ, Davidson EH, Wong WH, McMahon AP. 2007. Genomic characterization of Gli-activator targets in sonic hedgehog-mediated neural patterning. *Development* **134**: 1977–1989.
- Wang Y, Smedberg JL, Cai KQ, Capo-Chichi DC, Xu XX. 2011. Ectopic expression of GATA6 bypasses requirement for Grb2 in primitive endoderm formation. *Dev Dyn* **240**: 566–576.
- Yamanaka Y, Lanner F, Rossant J. 2010. FGF signal-dependent segregation of primitive endoderm and epiblast in the mouse blastocyst. *Development* **137**: 715–724.
- Yan L, Yang M, Guo H, Yang L, Wu J, Li R, Liu P, Lian Y, Zheng X, Yan J, et al. 2013. Single-cell RNA-seq profiling of human pre-implantation embryos and embryonic stem cells. *Nat Struct Mol Biol* **20**: 1131–1139.
- Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A. 2008. The ground state of embryonic stem cell self-renewal. *Nature* **453**: 519–523.
- Yu M, Riva L, Xie H, Schindler Y, Moran TB, Cheng Y, Yu D, Hardison R, Weiss MJ, Orkin SH, et al. 2009. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. *Mol Cell* **36**: 682–695.
- Zaret KS, Carroll JS. 2011. Pioneer transcription factors: establishing competence for gene expression. *Genes Dev* **25**: 2227–2241.
- Zhang X, Zhang J, Wang T, Esteban MA, Pei D. 2008. Esrrb activates Oct4 transcription and sustains self-renewal and pluripotency in embryonic stem cells. *J Biol Chem* **283**: 35825–35833.
- Zhou Q, Chipperfield H, Melton DA, Wong WH. 2007. A gene regulatory network in mouse embryonic stem cells. *Proc Natl Acad Sci* **104**: 16438–16443.
- Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. 2008. In vivo reprogramming of adult pancreatic exocrine cells to β -cells. *Nature* **455**: 627–632.